Comparing ASLAN Pharmaceuticals (NASDAQ:ASLN) & Addex Therapeutics (OTCMKTS:ADDXF)

Addex Therapeutics (OTCMKTS:ADDXF) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Risk and Volatility

Addex Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Addex Therapeutics and ASLAN Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	0	0	0	0	N/A
ASLAN Pharmaceuticals	0	0	3	0	3.00

ASLAN Pharmaceuticals has a consensus price target of $15.67, indicating a potential upside of 1,421.04%. Given ASLAN Pharmaceuticals’ higher possible upside, analysts clearly believe ASLAN Pharmaceuticals is more favorable than Addex Therapeutics.

Valuation & Earnings

This table compares Addex Therapeutics and ASLAN Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
ASLAN Pharmaceuticals	$12.00 million	1.40	-$51.38 million	($3.00)	-0.34

Addex Therapeutics has higher earnings, but lower revenue than ASLAN Pharmaceuticals.

Institutional and Insider Ownership

42.2% of ASLAN Pharmaceuticals shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Addex Therapeutics and ASLAN Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	N/A	N/A
ASLAN Pharmaceuticals	N/A	-761.25%	-81.66%

Summary

ASLAN Pharmaceuticals beats Addex Therapeutics on 6 of the 8 factors compared between the two stocks.

About Addex Therapeutics

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.